Antimalarial drugs are key tools for the control and elimination of malaria. Recent decreases
in the global malaria burden are likely due, in part, to the deployment of artemisinin-based …

Controlling the spread of antimalarial drug resistance, especially resistance of P lasmodium
falciparum to artemisinin‐based combination therapies, is a high priority. Available data …

In regions with high malaria endemicity, the withdrawal of chloroquine (CQ) as first-line
treatment of Plasmodium falciparum infections has typically led to the restoration of CQ …

The combination of piperaquine and dihydroartemisinin has recently become the official first-
line therapy in several Southeast Asian countries. The pharmacokinetic mismatching of …

Background The emergence of artemisinin-resistant P. falciparum malaria in South-East
Asia highlights the need for continued global surveillance of the efficacy of artemisinin …

Artemether–lumefantrine (AL) and artesunate–amodiaquine (AS-AQ) are the most
commonly used artemisinin-based combination therapies (ACT) for treatment of …

Abstract Background. Multidrug-resistant Plasmodium falciparum is a major threat to global
malaria control. Parasites develop resistance by gradually acquiring genetic polymorphisms …

Malaria is a life-threatening tropical disease caused by parasites of the genus Plasmodium,
of which Plasmodium falciparum is the most lethal. Malaria parasites have a complex life …

Artemisinin-based combination regimens are recommended by WHO for the treatment of
uncomplicated Plasmodium falciparum malaria. One such combination comprises the …

Background. Artemisinin-based combination therapies, including artemether-lumefantrine
(AL) and dihydroartemisinin-piperaquine (DP), are recommended to treat uncomplicated …